Benign Prostatic Hyperplasia Treatment Market Size, Key Drivers, Trends And Opportunities to 2033

Table Of Content

Executive Summary

Research Scope & Segmentation

Research Objectives
Limitations & Assumptions
Market Scope & Segmentation
Currency & Pricing Considered

Market Opportunity Assessment

Emerging Regions / Countries
Emerging Companies
Emerging Applications / End Use

Market Trends

Drivers
Market Warning Factors
Latest Macro Economic Indicators
Geopolitical Impact
Technology Factors

Market Assessment

Porters Five Forces Analysis
Value Chain Analysis

Regulatory Framework

North America
Europe
APAC
Middle East and Africa
LATAM

ESG Trends

Global Benign Prostatic Hyperplasia Treatment Market Size Analysis

Global Benign Prostatic Hyperplasia Treatment Market Introduction
By Treatment Type
1. Introduction
  1. Treatment Type By Value
2. Pharmacological Treatment (Alpha-blockers, 5-Alpha Reductase Inhibitors, Phosphodiesterase-5 Inhibitors, Others)
  1. By Value
3. Minimally Invasive Procedures (Transurethral Resection of the Prostate [TURP], Laser Therapy, Prostatic Urethral Lift [UroLift], Prostatic Artery Embolisation [PAE], Others)
  1. By Value
4. Surgical Procedures (Open Prostatectomy, Robotic-Assisted Surgery, Others)
  1. By Value
By End-User
1. Introduction
  1. End-User By Value
2. Hospitals
  1. By Value
3. Ambulatory Surgical Centers (ASCs)
  1. By Value
4. Clinics
  1. By Value
5. Home Care Settings
  1. By Value
By Distribution Channel:
1. Introduction
  1. Distribution Channel: By Value
2. Hospital Pharmacies
  1. By Value
3. Retail Pharmacies
  1. By Value
4. Online Pharmacies
  1. By Value

North America Market Analysis

Introduction
By Treatment Type
1. Introduction
  1. Treatment Type By Value
2. Pharmacological Treatment (Alpha-blockers, 5-Alpha Reductase Inhibitors, Phosphodiesterase-5 Inhibitors, Others)
  1. By Value
3. Minimally Invasive Procedures (Transurethral Resection of the Prostate [TURP], Laser Therapy, Prostatic Urethral Lift [UroLift], Prostatic Artery Embolisation [PAE], Others)
  1. By Value
4. Surgical Procedures (Open Prostatectomy, Robotic-Assisted Surgery, Others)
  1. By Value
By End-User
1. Introduction
  1. End-User By Value
2. Hospitals
  1. By Value
3. Ambulatory Surgical Centers (ASCs)
  1. By Value
4. Clinics
  1. By Value
5. Home Care Settings
  1. By Value
By Distribution Channel:
1. Introduction
  1. Distribution Channel: By Value
2. Hospital Pharmacies
  1. By Value
3. Retail Pharmacies
  1. By Value
4. Online Pharmacies
  1. By Value
U.S.
1. By Treatment Type
  1. Introduction
    1. Treatment Type By Value
  2. Pharmacological Treatment (Alpha-blockers, 5-Alpha Reductase Inhibitors, Phosphodiesterase-5 Inhibitors, Others)
    1. By Value
  3. Minimally Invasive Procedures (Transurethral Resection of the Prostate [TURP], Laser Therapy, Prostatic Urethral Lift [UroLift], Prostatic Artery Embolisation [PAE], Others)
    1. By Value
  4. Surgical Procedures (Open Prostatectomy, Robotic-Assisted Surgery, Others)
    1. By Value
2. By End-User
  1. Introduction
    1. End-User By Value
  2. Hospitals
    1. By Value
  3. Ambulatory Surgical Centers (ASCs)
    1. By Value
  4. Clinics
    1. By Value
  5. Home Care Settings
    1. By Value
3. By Distribution Channel:
  1. Introduction
    1. Distribution Channel: By Value
  2. Hospital Pharmacies
    1. By Value
  3. Retail Pharmacies
    1. By Value
  4. Online Pharmacies
    1. By Value
Canada

Europe Market Analysis

Introduction
By Treatment Type
1. Introduction
  1. Treatment Type By Value
2. Pharmacological Treatment (Alpha-blockers, 5-Alpha Reductase Inhibitors, Phosphodiesterase-5 Inhibitors, Others)
  1. By Value
3. Minimally Invasive Procedures (Transurethral Resection of the Prostate [TURP], Laser Therapy, Prostatic Urethral Lift [UroLift], Prostatic Artery Embolisation [PAE], Others)
  1. By Value
4. Surgical Procedures (Open Prostatectomy, Robotic-Assisted Surgery, Others)
  1. By Value
By End-User
1. Introduction
  1. End-User By Value
2. Hospitals
  1. By Value
3. Ambulatory Surgical Centers (ASCs)
  1. By Value
4. Clinics
  1. By Value
5. Home Care Settings
  1. By Value
By Distribution Channel:
1. Introduction
  1. Distribution Channel: By Value
2. Hospital Pharmacies
  1. By Value
3. Retail Pharmacies
  1. By Value
4. Online Pharmacies
  1. By Value
U.K.
1. By Treatment Type
  1. Introduction
    1. Treatment Type By Value
  2. Pharmacological Treatment (Alpha-blockers, 5-Alpha Reductase Inhibitors, Phosphodiesterase-5 Inhibitors, Others)
    1. By Value
  3. Minimally Invasive Procedures (Transurethral Resection of the Prostate [TURP], Laser Therapy, Prostatic Urethral Lift [UroLift], Prostatic Artery Embolisation [PAE], Others)
    1. By Value
  4. Surgical Procedures (Open Prostatectomy, Robotic-Assisted Surgery, Others)
    1. By Value
2. By End-User
  1. Introduction
    1. End-User By Value
  2. Hospitals
    1. By Value
  3. Ambulatory Surgical Centers (ASCs)
    1. By Value
  4. Clinics
    1. By Value
  5. Home Care Settings
    1. By Value
3. By Distribution Channel:
  1. Introduction
    1. Distribution Channel: By Value
  2. Hospital Pharmacies
    1. By Value
  3. Retail Pharmacies
    1. By Value
  4. Online Pharmacies
    1. By Value
Germany
France
Spain
Italy
Russia
Nordic
Benelux
Rest of Europe

APAC Market Analysis

Introduction
By Treatment Type
1. Introduction
  1. Treatment Type By Value
2. Pharmacological Treatment (Alpha-blockers, 5-Alpha Reductase Inhibitors, Phosphodiesterase-5 Inhibitors, Others)
  1. By Value
3. Minimally Invasive Procedures (Transurethral Resection of the Prostate [TURP], Laser Therapy, Prostatic Urethral Lift [UroLift], Prostatic Artery Embolisation [PAE], Others)
  1. By Value
4. Surgical Procedures (Open Prostatectomy, Robotic-Assisted Surgery, Others)
  1. By Value
By End-User
1. Introduction
  1. End-User By Value
2. Hospitals
  1. By Value
3. Ambulatory Surgical Centers (ASCs)
  1. By Value
4. Clinics
  1. By Value
5. Home Care Settings
  1. By Value
By Distribution Channel:
1. Introduction
  1. Distribution Channel: By Value
2. Hospital Pharmacies
  1. By Value
3. Retail Pharmacies
  1. By Value
4. Online Pharmacies
  1. By Value
China
1. By Treatment Type
  1. Introduction
    1. Treatment Type By Value
  2. Pharmacological Treatment (Alpha-blockers, 5-Alpha Reductase Inhibitors, Phosphodiesterase-5 Inhibitors, Others)
    1. By Value
  3. Minimally Invasive Procedures (Transurethral Resection of the Prostate [TURP], Laser Therapy, Prostatic Urethral Lift [UroLift], Prostatic Artery Embolisation [PAE], Others)
    1. By Value
  4. Surgical Procedures (Open Prostatectomy, Robotic-Assisted Surgery, Others)
    1. By Value
2. By End-User
  1. Introduction
    1. End-User By Value
  2. Hospitals
    1. By Value
  3. Ambulatory Surgical Centers (ASCs)
    1. By Value
  4. Clinics
    1. By Value
  5. Home Care Settings
    1. By Value
3. By Distribution Channel:
  1. Introduction
    1. Distribution Channel: By Value
  2. Hospital Pharmacies
    1. By Value
  3. Retail Pharmacies
    1. By Value
  4. Online Pharmacies
    1. By Value
Korea
Japan
India
Australia
Taiwan
South East Asia
Rest of Asia-Pacific

Middle East and Africa Market Analysis

Introduction
By Treatment Type
1. Introduction
  1. Treatment Type By Value
2. Pharmacological Treatment (Alpha-blockers, 5-Alpha Reductase Inhibitors, Phosphodiesterase-5 Inhibitors, Others)
  1. By Value
3. Minimally Invasive Procedures (Transurethral Resection of the Prostate [TURP], Laser Therapy, Prostatic Urethral Lift [UroLift], Prostatic Artery Embolisation [PAE], Others)
  1. By Value
4. Surgical Procedures (Open Prostatectomy, Robotic-Assisted Surgery, Others)
  1. By Value
By End-User
1. Introduction
  1. End-User By Value
2. Hospitals
  1. By Value
3. Ambulatory Surgical Centers (ASCs)
  1. By Value
4. Clinics
  1. By Value
5. Home Care Settings
  1. By Value
By Distribution Channel:
1. Introduction
  1. Distribution Channel: By Value
2. Hospital Pharmacies
  1. By Value
3. Retail Pharmacies
  1. By Value
4. Online Pharmacies
  1. By Value
UAE
1. By Treatment Type
  1. Introduction
    1. Treatment Type By Value
  2. Pharmacological Treatment (Alpha-blockers, 5-Alpha Reductase Inhibitors, Phosphodiesterase-5 Inhibitors, Others)
    1. By Value
  3. Minimally Invasive Procedures (Transurethral Resection of the Prostate [TURP], Laser Therapy, Prostatic Urethral Lift [UroLift], Prostatic Artery Embolisation [PAE], Others)
    1. By Value
  4. Surgical Procedures (Open Prostatectomy, Robotic-Assisted Surgery, Others)
    1. By Value
2. By End-User
  1. Introduction
    1. End-User By Value
  2. Hospitals
    1. By Value
  3. Ambulatory Surgical Centers (ASCs)
    1. By Value
  4. Clinics
    1. By Value
  5. Home Care Settings
    1. By Value
3. By Distribution Channel:
  1. Introduction
    1. Distribution Channel: By Value
  2. Hospital Pharmacies
    1. By Value
  3. Retail Pharmacies
    1. By Value
  4. Online Pharmacies
    1. By Value
Turkey
Saudi Arabia
South Africa
Egypt
Nigeria
Rest of MEA

LATAM Market Analysis

Introduction
By Treatment Type
1. Introduction
  1. Treatment Type By Value
2. Pharmacological Treatment (Alpha-blockers, 5-Alpha Reductase Inhibitors, Phosphodiesterase-5 Inhibitors, Others)
  1. By Value
3. Minimally Invasive Procedures (Transurethral Resection of the Prostate [TURP], Laser Therapy, Prostatic Urethral Lift [UroLift], Prostatic Artery Embolisation [PAE], Others)
  1. By Value
4. Surgical Procedures (Open Prostatectomy, Robotic-Assisted Surgery, Others)
  1. By Value
By End-User
1. Introduction
  1. End-User By Value
2. Hospitals
  1. By Value
3. Ambulatory Surgical Centers (ASCs)
  1. By Value
4. Clinics
  1. By Value
5. Home Care Settings
  1. By Value
By Distribution Channel:
1. Introduction
  1. Distribution Channel: By Value
2. Hospital Pharmacies
  1. By Value
3. Retail Pharmacies
  1. By Value
4. Online Pharmacies
  1. By Value
Brazil
1. By Treatment Type
  1. Introduction
    1. Treatment Type By Value
  2. Pharmacological Treatment (Alpha-blockers, 5-Alpha Reductase Inhibitors, Phosphodiesterase-5 Inhibitors, Others)
    1. By Value
  3. Minimally Invasive Procedures (Transurethral Resection of the Prostate [TURP], Laser Therapy, Prostatic Urethral Lift [UroLift], Prostatic Artery Embolisation [PAE], Others)
    1. By Value
  4. Surgical Procedures (Open Prostatectomy, Robotic-Assisted Surgery, Others)
    1. By Value
2. By End-User
  1. Introduction
    1. End-User By Value
  2. Hospitals
    1. By Value
  3. Ambulatory Surgical Centers (ASCs)
    1. By Value
  4. Clinics
    1. By Value
  5. Home Care Settings
    1. By Value
3. By Distribution Channel:
  1. Introduction
    1. Distribution Channel: By Value
  2. Hospital Pharmacies
    1. By Value
  3. Retail Pharmacies
    1. By Value
  4. Online Pharmacies
    1. By Value
Mexico
Argentina
Chile
Colombia
Rest of LATAM

Competitive Landscape

Benign Prostatic Hyperplasia Treatment Market Share By Players
M&A Agreements & Collaboration Analysis

Market Players Assessment

Boston Scientific Corporation
1. Overview
2. Business Information
3. Revenue
4. ASP
5. SWOT Analysis
6. Recent Developments
Teleflex Incorporated
Olympus Corporation
GlaxoSmithKline plc
Pfizer Inc.
Astellas Pharma Inc.
Merck & Co., Inc.
AbbVie Inc.
Endo International plc
Urologix, LLC
Sanofi S.A.
Asahi Kasei Corporation
Medtronic plc
PROCEPT BioRobotics Corporation
Lumenis Ltd.

Research Methodology

Research Data
1. Secondary Data
  1. Major secondary sources
  2. Key data from secondary sources
2. Primary Data
  1. Key data from primary sources
  2. Breakdown of primaries
3. Secondary And Primary Research
  1. Key industry insights
Market Size Estimation
1. Bottom-Up Approach
2. Top-Down Approach
3. Market Projection
Research Assumptions
1. Assumptions
Limitations
Risk Assessment